Opioid Treatments Could Get Survival Claim As US FDA Develops Protocol
Executive Summary
Commissioner Gottlieb announces several actions in the works to promote development of new treatments for opioid addiction, including guidance on how to establish novel endpoints.
You may also be interested in...
Opioid Use Disorder: Is Reduced Usage A Better Endpoint Than Abstinence?
Some at patient-focused drug development meeting argue that cutting opioid use should not be considered treatment failure and that medications allowing controlled opioid use may be beneficial.
FDA's Kratom Campaign Turns To Firms Destroying Inventory, Recalling Products
FDA announcement that Missouri firm Divinity Products will recall and destroy kratom was part of the agency's latest warning that ingredients derived from the herb are not safe for use in supplements or for therapeutic use to treat symptoms of withdrawal from opioid abuse. FDA doesn't get agreement from the kratom sector about the herb's status as a dietary ingredient as well as its safety profile.
BIO Report: Attrition Higher For Novel Pain Candidates Than In Other Diseases, Funding Lacking
A new report released during the BIO CEO conference shows novel pain therapy candidates face a high failure rate, which may help explain why smaller, privately held biotechs aren't very active in the space.